Cancer immunotherapy provides durable response to a small subset of treated patients. A variety of approaches are being developed to increase the long term benefit of checkpoint blockade. These include radiation and cytotoxic therapies and use of cancer vaccines among others. Preclinical and clinical studies have demonstrated that cancer vaccines evoke strong anti-tumor immune response by mobilizing CD8+ T-cells. A challenge in the field of cancer vaccines is identifying mutations that are T-cell activating (neoepitopes). Advances in next generation sequencing permit accurate detection of cancer mutations, even when present at a low frequency. However, neoepitope prediction involves a large number of steps many of which cannot be accurately modeled. In humans, class-I peptides, 9-11-mer in length are presented by HLA -A, B and C alleles and activate CD8 + T-cells.
